Aytu BioPharma (AYTU) earnings
Aytu BioPharma earnings: last reported Tue, 22 Sep 2026, for the quarter ended Jun 2026.
Aytu BioPharma earnings callsAytu BioPharma earnings calls (AYTU)
Aytu BioPharma Q4 FY26 — EXXUA Momentum and Return to Positive Adjusted EBITDA
What went well
- EXXUA net revenue grew to $3.9 million in Q4 FY26, up from $2.4 million in Q3 FY26.
- Aytu returned to positive adjusted EBITDA of $0.5 million in Q4 FY26, compared to a negative $2.8 million in Q3 FY26.
- EXXUA sales specialist productivity more than doubled, from ~18 prescriptions per rep per month in March to ~43 in July.
What to watch
- ADHD portfolio net revenue of $10.4 million in Q4 FY26 was down from $13.1 million in the prior year period.
- Sales force adjustments temporarily reduced EXXUA coverage, with headcount dropping from 43 reps in March to 32 in July, before recovering to 42.
Performance +25.1% 1Y
1Y: $1.71 on 29 Sept 2025 → $2.14. High $2.9 (5 Jan 2026), low $1.71 (29 Sept 2025).
Quarterly results
Q2 FY26: revenue up 6.4%, net profit up 99.9% against the same quarter last year.
| Line item | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 17 | 16 | 18 | 15 | 14 −16% | 15 −7% | 12 −33% | 16 +6% |
| EBITDA | -1 | -2 | 2 | -8 | -2 −62% | -2 −16% | -4 −268% | -1 +90% |
| Net profit | 1 | 1 | 4 | -20 | 2 +33% | -11 −1443% | -6 −241% | -0 +100% |
How to read this
US$ million, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Balance sheet
| Year ending | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Jun 2026 |
|---|---|---|---|---|---|---|
| Equity capital | $3.0K | $4.0K | $1.0K | $1.0K | $1.0K | $1.0K |
| Reserves | -$178.30M | -$287.08M | -$304.13M | -$319.97M | -$333.54M | -$347.79M |
| Total liabilities | $128.10M | $93.31M | $97.11M | $90.38M | $105.21M | $69.73M |
| Fixed assets | $5.14M | $3.02M | $1.81M | $693.0K | $532.0K | $385.0K |
| Total assets | $265.67M | $137.62M | $136.46M | $118.09M | $124.18M | $105.01M |
How to read this
As filed on each reporting date, including interim balance sheets. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Insider filings
19 filings between Oct 3, 2025 and Jul 28, 2026.
Open market
decisions to buy or sellNobody bought or sold AYTU on the open market in this window. The filings below are 19 awards.
Compensation
not trading decisions- 19
- Award — granted as compensation
Latest filings (32)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 28, 2026 | Selhorn Ryan J Chief Financial Officer | Award | 25,000 | $0 |
| Jul 28, 2026 | Disbrow Jarrett Chief Business Officer | Award | 15,000 | $0 |
| Jul 28, 2026 | PYSZCZYMUKA GREG Chief Commercial Officer | Award | 20,000 | $0 |
| Jul 28, 2026 | Disbrow Joshua R. Chief Executive Officer | Award | 30,000 | $0 |
| Jul 28, 2026 | DOCKERY CARL Director | Award | 10,000 | $0 |
| Jul 28, 2026 | Donofrio John Jr. Director | Award | 10,000 | $0 |
| Jul 28, 2026 | JAIN ABHINAV Director | Award | 10,000 | $0 |
| Jul 28, 2026 | LIU VIVIAN H Director | Award | 10,000 | $0 |
| Oct 3, 2025 | Selhorn Ryan J Chief Financial Officer | Award | 17,500 | $0 |
| Oct 3, 2025 | Disbrow Jarrett Chief Business Officer | Award | 12,500 | $0 |
| Oct 3, 2025 | PYSZCZYMUKA GREG Chief Commercial Officer | Award | 12,500 | $0 |
| Oct 3, 2025 | Disbrow Jarrett Chief Business Officer | Award | 19,606 | $0 |
| Oct 3, 2025 | Donofrio John Jr. Director | Award | 10,000 | $0 |
| Oct 3, 2025 | DOCKERY CARL Director | Award | 10,000 | $0 |
| Oct 3, 2025 | JAIN ABHINAV Director | Award | 10,000 | $0 |
| Oct 3, 2025 | LIU VIVIAN H Director | Award | 10,000 | $0 |
| Oct 3, 2025 | Disbrow Joshua R. Chief Executive Officer | Award | 31,446 | $0 |
| Oct 3, 2025 | Disbrow Joshua R. Chief Executive Officer | Award | 22,500 | $0 |
| Oct 3, 2025 | Selhorn Ryan J Chief Financial Officer | Award | 16,243 | $0 |
| Jun 9, 2025 | Disbrow Joshua R. Chief Executive Officer | Purchase | 66,666 | $100.0K |
| Jun 9, 2025 | Disbrow Jarrett Chief Business Officer | Purchase | 16,666 | $25.0K |
| Mar 31, 2025 | PYSZCZYMUKA GREG Chief Commercial Officer | Option exercise | 209 | — |
| Feb 28, 2025 | Disbrow Joshua R. Chief Executive Officer | Purchase | 15,000 | $19.5K |
| Feb 5, 2025 | Selhorn Ryan J Chief Financial Officer | Option exercise | 105 | — |
| Dec 31, 2024 | PYSZCZYMUKA GREG Chief Commercial Officer | Option exercise | 208 | — |
| Nov 11, 2024 | Selhorn Ryan J Chief Financial Officer | Award | 14,000 | $0 |
| Nov 6, 2024 | LIU VIVIAN H Director | Award | 1,500 | $0 |
| Nov 6, 2024 | JAIN ABHINAV Director | Award | 1,500 | $0 |
| Nov 6, 2024 | Donofrio John Jr. Director | Award | 1,500 | $0 |
| Nov 6, 2024 | DOCKERY CARL Director | Award | 1,500 | $0 |
| Sep 30, 2024 | PYSZCZYMUKA GREG Chief Commercial Officer | Option exercise | 209 | — |
| Aug 11, 2023 | LIU VIVIAN H Director | Award | 1,500 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.